ROS1 (ROS proto-oncogene 1 , receptor tyrosine kinase) by Klempner, Samuel J & Ou, Sai-Hong
Gene Section 
Short Communication 
Atlas Genet Cytogenet Oncol Haematol. 2015; 19(5) 337 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
ROS1 (ROS proto-oncogene 1 , receptor 
tyrosine kinase) 
Samuel J Klempner, Sai-Hong Ou 
University of California Irvine Medical Center, Orange, CA. sklempne@uci.edu; siou@uci.edu 
Published in Atlas Database: January 2014 
Online updated version : http://AtlasGeneticsOncology.org/Genes/ROS1ID42144ch6q22.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/62121/01-2014-ROS1ID42144ch6q22.pdf 
DOI: 10.4267/2042/62121 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2015 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
ROS1 is proto-oncogene encoding a type I integral 
membrane protein with receptor tyrosine kinase 
(RTK) activity.   
ROS1 is a member of the insulin receptor family 
and is involved in downstream signalling processes 
involved in cell growth and differentiation. 
Keywords 
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Identity 
Other names: c-ros-1, MCF3, ROS 
HGNC (Hugo): ROS1 
Location: 6q22.1 
Note 
ROS1 is proto-oncogene encoding a type I integral 
membrane protein with receptor tyrosine kinase 
(RTK) activity.   
ROS1 is a member of the insulin receptor family 
and is involved in downstream signalling processes 
involved in cell growth and differentiation. 
DNA/RNA 
Description 
The ROS1 gene is highly conserved from 
drosophila through zebrafish, rat, cow, rhesus, and 
homo sapiens. Refseq NM_002944. 
Protein 
Description 
ROS1 gene encodes a 2,347 amino acid protein 
with a molecular weight of 263,915 Daltons (NCBI: 
P08922).  This protein is a type I single pass 
integral membrane protein with tyrosine kinase 
activity. SwissProt identifier P08922, Protein 
NP_002935 
Expression 
ROS1 expression is involved in regionalization of 
the proximal epididymal epithelium. Expression 
levels have been highest in liver, platelelts, T-cells 
and monocytes, but is found across nearly all cell 
types. 
Localisation 
ROS1 is localized to the cell plasma membrane and 
contains both extracellular and intracellular 
domains. 
Function 
ROS1 functions as an orphan receptor tyrosine 
kinase with an unestablished ligand.  ROS1 directly 
interacts via an SH2 1 domain with PTPN6 which 
drives ROS1 dephosphorylation (Charest et al., 
2006). ROS1 has also been suggested to interact 
with PTPN11 leading to PI3K/mTOR signaling, 
and to mediate phosphorylation of VAV3 (Charest 
et al., 2006). The ligand for wild type ROS1 is 
unknown and the normal function remains unclear 
despite the above associations. 
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Homology 
ROS1 shares significant homology with other 
members of the insulin growth factor receptor 
family, and the gene is highly conserved back 
through drosophila melanogaster. 
Mutations 
Germinal 
None established. 
Somatic 
The intrachromosomal del(6)(q21q22) deletion has 
been identified in glioblastoma multiforme and 
leads to the formation of a constitutive active 
GOPC-ROS1 protein (Charest et al., 2003). In non-
small cell lung cancer (NSCLC) the SLC34A2-
ROS1 chimeric protein also holds kinase activity.  
A CD74-ROS1 chimeric protein has also been 
identified in NSCLC (Awad et al., 2013). 
Implicated in 
Non-small cell lung cancer, renal 
oncocytoma, gastric cancer, 
glioblastoma multiforme, 
cholangiocarcinoma  colorectal 
cancer. 
Note 
There has been a rapidly expanding appreciation of 
ROS1 fusion proteins in the tumorigenesis of 
multiple malignancies as discussed below (Charest 
et. al., 2003, Gu et al., 2011, Rimkunas et al., 2012, 
Takeuchi et al.,2012, Awad et al., 2013, Lee et al., 
2013). 
 
 
Disease 
ROS1 rearrangements occur in <2% of NSCLC and 
are enriched for in adenocarcinoma and young 
never smokers (Bergethon et al., 2012). 
Prognosis 
To date ROS1 has not been clearly implicated as an 
independent prognostic variable. ROS1 
rearrangements may predict sensitivity to the ALK-
inhibitor Crizotinib in NSCLC.  Small molecule 
inhibitor screens have also identified foretinib as a 
potent inhibitor of multiple ROS1 fusion proteins. 
Additionaly, ROS1 mutation has been observed as a 
acquired resistance mechanism to crizotinib. 
Davare and colleagues have shown that foretinib is 
capable of inhibiting the G2032R ROS1 mutant 
which is resistant to crizotinib (Davare et al., 2013). 
Cytogenetics 
ROS1 rearrangements have been documented with 
the following fusion partners; CCDC6, CD74, 
CEP85L, also called C6orf204, CLTC, EZR, 
GOPC, KDELR2, LRIG3, SDC4, SLC34A2, and 
TPM3. 
Translocations and fusion proteins: t(1;6)(q21;q22) 
TPM3/ROS1; t(4;6)(p15;q22) SLC34A2/ROS1; 
t(5;6)(q33;q22) CD74/ROS1; t(6;6)(q22;q22) 
GOPC/ROS1; t(6;6)(q22;q22) CEP85L/ROS1; 
t(6;6)(q22;q25) EZR/ROS1; t(6;7)(q22;p22) 
KDELR2/ROS1; t(6;10)(q22;q21) CCDC6/ROS1; 
t(6;12)(q22;q14) LRIG3/ROS1; 
t(6;17)(q22;q23)CLTC/ROS1; t(6;20)(q22;q12) 
SDC4/ROS1 (Charest et. Al., 2003, Gu et al., 2011, 
Rimkunas et al., 2012, Takeuchi et al., 2012, Awad 
et al., 2013, Lee et al., 2013, Mitelman et al., 2015).  
Within NSCLC ROS1 rearrangements are non-
overlapping with EGFR, KRAS, and ALK genomic  
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alterations (Davies et al., 2012, Awad et al., 2013, 
Go et al., 2013). 
Breakpoints 
Note 
Within the COSMIC database ROS1 chromosomal 
rearrangements have been documented with the 
following fusion partners ; CD74, EZR, GOPC, 
SDC4, TPM3, SLC34A2, and LRIG3 (COSMIC, 
accessed 12/2013). 
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